pharmaphorum

NOVEMBER 11, 2022

Viehbacher led Sanofi between 2008 and 2014 and has decades of experience with both large pharmaceutical companies and small biotechs. However, in 2014 Sanofi fired Viehbacher over a boardroom fight regarding his management. Biogen’s shares rose 2.4% to $289.01 in pre-market trading following the announcement.

Insurance 40

Insurance Doctors FDA Pharma 40

pharmaphorum

SEPTEMBER 27, 2022

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs. That resulted in false claims for payment being submitted to the government healthcare programs Medicare and Medicaid, it alleged. .”

Government 44

Government Doctors Consulting Training 44

Pharmaceutical Technology

OCTOBER 5, 2022

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs. Biogen’s activity in multiple sclerosis.

Government 59

Government Specialization Physicians Education 59

European Pharmaceutical Review

AUGUST 23, 2022

The US Food and Drug Administration (FDA) further estimates that 97 percent of online pharmacies are operating illegally. We hope that this article serves draws attention from the community and makes funding agencies aware of this imperative healthcare sustainability problem. About the author. 2019; Available from: [link].

Medicine 87

Medicine Food and Drug Administration Pharmaceutical products Pharmaceutical 87

Evolve Your Success

JANUARY 23, 2024

The negotiation with the hospital, the shipping across boundaries, frontiers, FDA, and non-FDA is very interesting. It’s very interesting, all the way to the surgical procedure, the recovery, and to 2 or 3 years later, which is the patient record and outcome tracking. It’s a very interesting business. This is it.

Medical sales 52

Medical sales Medical Sales Physicians 52

Pharmaceutical Technology

JANUARY 6, 2023

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. In September, Novartis sent the FDA a petition, after a similar one was rejected in April 2021, asking for Entresto’s patent protection to be extended to February 2024.

Pharmaceutical 97

Pharmaceutical Doctors Healthcare Provider Prescription 97